In April 2026, Mabwell (688062.SH) announced NMPA’s acceptance of its world’s first LILRB4/CD3-targe

Liver injury can deteriorate into acute liver failure, posing a severe threat to life. As an antimal

Fluoropharm will participate in the 24th CPHI China 2026, which will be held in Shanghai, China from

Ovarian cancer is known as the 'silent killer' due to the hidden nature of its early symptom

Recently, the FDA released a draft guidance titled 'Development of Non-Opioid Analgesics for the

Ifinatamab deruxtecan is a potentially first-in-class antibody-drug conjugate (ADC) targeting B7-H3,

Sodium fluorine [18F] injection is a positron emission tomography (PET) radioimaging agent used in b

On June 27, 2025, China's National Medical Products Administration (NMPA) announced the approval

Recently, researchers found that after 18 months of treatment with evolocumab, patients with coronar

Our company will participate in CPHI China 2025 in Shanghai New International Expo Center from June